Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Go back to Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study| Gilead Sciences (NASDAQ: GILD) | Delayed: 130.34 +0.06 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.28 | 52 Week High | $108.63 | |||
| Open | $131.83 | 52 Week Low | $71.39 | |||
| Day High | $132.86 | P/E | 72.01 | |||
| Day Low | $130.23 | EPS | $1.81 | |||
| Volume | 4,757,560 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 127.47 +1.21 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.26 | 52 Week High | $65.46 | |||
| Open | $127.32 | 52 Week Low | $47.97 | |||
| Day High | $128.83 | P/E | 86.71 | |||
| Day Low | $126.62 | EPS | $1.47 | |||
| Volume | 7,792,424 | |||||
